Floatz logo

Sep-380135

Schizophrenia

Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

144 Active assets in the Schizophrenia cohort.

Asset / SponsorPhaseRating
Lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Asenapine
Noven Pharmaceuticals, Inc.
Phase 4BBB
Xanomeline
European Group for Research In Schizophrenia
Phase 4BBB
TROSPIUM
European Group for Research In Schizophrenia
Phase 4BBB
Opc-34712
Humanis Saglık Anonim Sirketi
Phase 4BBB

View all 50 →

Same molecule, other indications

Sep-380135 is also rated in:

major depressive disorderDormant
CC
Indicative ·
44 / 100
View asset →
bipolar disorderDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →